Pharm'Up

An E-platform for Learners

Paltusotine Makes History as First Oral, Once-Daily Treatment for Acromegaly

Paltusotine Makes History as First Oral, Once-Daily Treatment for Acromegaly

Pharm'Up

The FDA has approved paltusotine (Palsonify; Crinetics Pharmaceuticals, Inc), marking a historic milestone as the first once-daily,...

Critical Delay: High LDL-C Detection and the Elevated Risk of Heart Attack

Critical Delay: High LDL-C Detection and the Elevated Risk of Heart Attack

Pharm'Up

A retrospective study published in the European Heart Journal reveals that a delayed initiation of statin therapy...

Empowering the Front Line: How Pharmacists Can Revolutionize Immunization Access for Vulnerable Cancer Patients

Empowering the Front Line: How Pharmacists Can Revolutionize Immunization Access for Vulnerable Cancer Patients

Pharm'Up

Patients battling cancer are profoundly immunosuppressed due to their chemotherapy and other therapeutic regimens, placing them at...

IMS 2025: On-Body Injector (OBI) Technology Streamlines Oncology Care, Enhancing Safety and Efficiency for Pharmacists and Nurses

IMS 2025: On-Body Injector (OBI) Technology Streamlines Oncology Care, Enhancing Safety and Efficiency for Pharmacists and Nurses

Pharm'Up

At the 22nd annual International Myeloma Society (IMS) meeting, Xavier Leleu, MD, PhD, a leading hematologist from...

Alarming Rise in Pediatric Flu-Linked Neurological Complications Underscores Urgent Need for Vaccination

Alarming Rise in Pediatric Flu-Linked Neurological Complications Underscores Urgent Need for Vaccination

Pharm'Up

The 2024-25 U.S. flu season witnessed a deeply concerning surge in neurological complications among children infected with...

Biolinq Shine Receives Landmark FDA De Novo Classification as First Multi-Analyte Wearable for Type 2 Diabetes

Biolinq Shine Receives Landmark FDA De Novo Classification as First Multi-Analyte Wearable for Type 2 Diabetes

Pharm'Up

Biolinq Inc. has achieved a significant milestone in diabetes management with the FDA granting De Novo classification...

Collaborative Care and Pharmacist-Led Management of CDK4/6 Inhibitor Toxicities

Collaborative Care and Pharmacist-Led Management of CDK4/6 Inhibitor Toxicities

Pharm'Up

In the evolving landscape of HR-positive/HER2-negative breast cancer, Cyclin-Dependent Kinase 4/6 (CDK4/6) inhibitors have cemented their role...

Anito-cel CAR T-Cell Therapy Delivers Deep, Durable Responses and High MRD-Negativity in Relapsed/Refractory Multiple Myeloma

Anito-cel CAR T-Cell Therapy Delivers Deep, Durable Responses and High MRD-Negativity in Relapsed/Refractory Multiple Myeloma

Pharm'Up

New data presented at the 2025 International Myeloma Society Annual Meeting in Toronto, Canada, has revealed that...

PCSK9 Inhibitors, Including Inclisiran, Show Sustained and Significant Lipid Reduction in Familial Hypercholesterolemia

PCSK9 Inhibitors, Including Inclisiran, Show Sustained and Significant Lipid Reduction in Familial Hypercholesterolemia

Pharm'Up

A comprehensive new systematic review and meta-analysis published in Open Heart has affirmed the strong and sustained...

Breakthrough: New Injectable Therapy Could Prevent Heart Failure After Heart Attack Untitled

Untitled

Breakthrough: New Injectable Therapy Could Prevent Heart Failure After Heart Attack

Pharm'Up

Scientists from Northwestern University and the University of California San Diego have developed a groundbreaking, potent injectable...